Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of Deferasirox GPO in thalassemia patients with iron overload
TCTR20240601004Phase 2Recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in Thalassaemia and iron overload, sponsored by Government Pharmaceutical Organization. Started Jul 2023; status: recruiting.
02
Drugs
deferasirox
03
Conditions
Thalassaemiairon overload
Beyond the preview
Go deeper on TCTR20240601004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240601004.